Short term real-world Fingolimod efficacy and safety in Emirati patients with multiple sclerosis

Publication date: Available online 13 December 2019Source: Journal of Clinical NeuroscienceAuthor(s): Antonia Ceccarelli, Victoria Mifsud, Eslam Abusamra, Syed Irteza HussainAbstractIn clinical trials, Fingolimod was an efficacious and safe treatment for multiple sclerosis (MS). Despite this, few studies have explored its real-world efficacy and safety in the Middle East. The aim of this study was to describe our clinical experience with Fingolimod at Cleveland Clinic Abu Dhabi in Emirati patients with MS. We retrospectively collected clinical and brain and spinal cord MRI activity over time in 30 Emirati MS patients [F/M = 22/8, mean (SD) disease duration at treatment initiation = 3.3 (3.6) years, age at onset = 25.9 (6.9) years] who were commenced on Fingolimod from 2015 and followed for 18 months. The proportion of MS patients clinically and radiologically silent after Fingolimod initiation over time was assessed together with annualized relapse rate (ARR) reduction and adverse events (AEs) occurrence.70% of MS patients who started Fingolimod were naïve. The baseline ARR [mean (SD; range)] was [1.2 (0.8; 0–4)] and 23.3% of MS patients had Gadolinium enhancing lesions at baseline MRI. Overall, the ARR was reduced by 72% and, relapses and MRI activity were found in only 24% and 38% of MS patients respectively. Mild to moderate AEs were observed in 33% of MS patients. No severe AEs were recorded.In Emirati MS patients, Fingolimod is safe and efficacio...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research

Related Links:

Conclusion: New lesions at the reference MRI in terms of number and topography increase the risk of radiological disease activity during the follow up. PMID: 31959078 [PubMed - as supplied by publisher]
Source: Neurological Research - Category: Neurology Tags: Neurol Res Source Type: research
AbstractOxidative stress is a pathophysiological hallmark of many CNS diseases, among multiple sclerosis (MS). Accordingly, boosting the astrocytic transcription factor nuclear factor E2-related factor 2 (Nrf2) system in an MS mouse model efficiently ameliorates oligodendrocyte loss, neuroinflammation and axonal damage. Moreover, Dimethylfumarate, an efficient activator of Nrf2, has recently been approved as therapeutic option in MS treatment. Here, we use the cuprizone mouse model of MS to induce oxidative stress, selective oligodendrocyte loss, microglia and astrocyte activation as well as axonal damage in both wild type...
Source: Metabolic Brain Disease - Category: Neurology Source Type: research
Publication date: Available online 21 January 2020Source: Neuroscience &Biobehavioral ReviewsAuthor(s): M.C. Buscarinu, A. Fornasiero, M. Ferraldeschi, S. Romano, R. Reniè, E. Morena, C. Romano, G. Pellicciari, A.C. Landi, C. Fagnani, M. Salvetti, G. RistoriAbstractTwin studies of disease concordance are useful to weight the relative contribution of genetic and environmental factors to the cause of common complex disorders. In multiple sclerosis (MS) different twinning rates from geographic areas at different prevalence suggested that heritable and non-heritable factors contribute in different proportions and wa...
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research
DiscussionThe adapted MAM-36 showed adequate psychometric properties. However, indications of problematic targeting to PwMS with low disability emerged. For this reason, use of the scale appears to be more suitable among patients with moderate-to-severe disability.
Source: Neurological Sciences - Category: Neurology Source Type: research
ConclusionComorbidity increased the rate of all-cause, but not MS-specific, hospital admissions. Hospitalization rates were higher during the earlier stages of MS. Therefore, recognizing and managing comorbidity in the MS population, especially early in the disease course, will likely have the biggest impact on reducing overall hospital admissions.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
We describe a previously healthy elderly male who had no known malignancy. He presented with a demyelinating encephalomyelitis and later developed hemorrhagic changes on neuroimaging. He was treated with intravenous immunoglobulin (IVIG), intravenous steroids, and plasmapheresis; however, sustained clinical and radiographic stabilization and improvement only occurred following cyclophosphamide. He unexpectedly died of a cardiac arrest. Post-mortem, his serum paraneoplastic screen was found to be weakly positive for anti-CV2/CRMP5-Ab.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
ConclusionThe prevalence and incidence of MS in the Persian Gulf region has gone through significant changes during the past decades. This study highlights the need for future studies of MS prevalence and incidence, which will further elucidate the possible etiologies leading to periodical and geographical variations in MS incidence.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 21 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Rampichini Susanna, Gervasoni Elisa, Cattaneo Davide, Rovaris Marco, Grosso Cristina, Maggioni Martina Anna, Merati GiampieroAbstractBackground: Heart Rate Recovery (HRR) after a physical exercise has been poorly investigated in people with multiple sclerosis (PwMS).Objective: To evaluate the kinetics of HRR and its autonomic modulation in PwMS and to elucidate the interplay between HRR and subjective fatigue.Methods: ECG was digitally acquired during rest (5 min), submaximal exercise (4 min at 10 W of upper limb cy...
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Conditions:   Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Patient Engagement;   Self Efficacy Interventions:   Behavioral: PExMS and DECIMS-Wiki;   Behavioral: DECIMS-Wiki Sponsors:   Universitätsklinikum Hamburg-Eppendorf;   Roche Pharma AG;   Marianne-Strauss-Klinik, Berg, Germany;   Oslo Metropolitan University;   University of Luebeck;   Stiftung Lebensnerv, Berlin, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Lloyd A, Schofield H, Adlard N PMID: 31955617 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Brain | Clinical Trials | Gilenya | Middle East Health | Multiple Sclerosis | Neurology | Neuroscience | Study | UAE Health